Jan Birger Fredrik Toernell
Directeur/Membre du Conseil chez ABLIVA AB
Postes actifs de Jan Birger Fredrik Toernell
Sociétés | Poste | Début | Fin |
---|---|---|---|
ABLIVA AB | Directeur/Membre du Conseil | 27/04/2017 | - |
Independent Dir/Board Member | 27/04/2017 | - | |
University of Gothenburg | Corporate Officer/Principal | - | - |
Sahlgrenska University | Corporate Officer/Principal | - | - |
Innoext AB
Innoext AB Miscellaneous Commercial ServicesCommercial Services Innoext AB provides management consulting services. The private company is based in Västra Frölunda, Sweden. Jan Birger Fredrik Toernell has been the CEO of the Swedish company since 2011. | Directeur/Membre du Conseil | 01/07/2011 | - |
Directeur Général | 01/07/2011 | - | |
Lidds Pharma AB | Corporate Officer/Principal | - | - |
Aqilion AB
Aqilion AB Investment ManagersFinance Aqilion AB is a venture capital firm. The firm was founded in 2002 by Jan Ekberg and Mats G. Ringesten. It's headquartered in Helsingborg, Sweden. | Private Equity Investor | 29/05/2012 | - |
Glactone Pharma AB
Glactone Pharma AB Pharmaceuticals: MajorHealth Technology Glactone Pharma AB engages in the development of pipeline of novel signal transducer and activator of transcription 3 inhibitors. Its pipeline is used for immuno-oncology and for the treatment of drug resistant cancers, including castration resistant prostate cancer. The company was founded by Anders Sigvard Bjartell, Rebecka Hellsten, Martin Johansson, Eduardo Munoz, and Olov Arvid Sterner in 2012 and is headquartered in Helsingborg, Sweden. | Président | 01/07/2012 | - |
Stayble AB | Directeur/Membre du Conseil | - | - |
Diaprost AB
Diaprost AB Miscellaneous Commercial ServicesCommercial Services Diaprost AB is a private pharmaceutical research and development company based in Lund, Sweden. Diaprost collaborates with leading international experts in the fields of molecular medicine, biotechnology, immunology, radiology, radiation physics, laboratory medicine, and oncology. The Swedish company has an agreement with a top 10 pharma company for its first antibody H11B6 targeting the HK2 antigen, which is in early clinical development. The remaining Diaprost pipeline consists of 5A10, which targets free-PSA antigen for both diagnostic and therapeutic applications. The company was founded in 2005 with the aim of leveraging the transformative success of the PSA assay for detection of prostate cancer as a personalized theranostic platform. Johan Drott has been the CEO of the company since 2015. | Directeur/Membre du Conseil | 01/06/2012 | - |
░░░░░░ ░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - | - |
░░░░░░░░ | - | - | |
░░░░░░░░ ░░░░░░ ░░░░░░░░░░░ ░░ | ░░░░░░░░ | - | - |
Historique de carrière de Jan Birger Fredrik Toernell
Anciens postes connus de Jan Birger Fredrik Toernell
Sociétés | Poste | Début | Fin |
---|---|---|---|
░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
░░░░░░ ░░░░░░░ ░░ | ░░░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - | |
░░░░░░░ ░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░░░ ░░░░░░░ ░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - | - |
░░░░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
░░░░░░░ ░░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░░░ ░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | - |
░░░░░ ░░ | ░░░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | - | - |
Formation de Jan Birger Fredrik Toernell
University of Gothenburg | Doctorate Degree |
Statistiques
Internationale
Suède | 19 |
Royaume-Uni | 2 |
Opérationnelle
Director/Board Member | 6 |
Chairman | 5 |
Corporate Officer/Principal | 5 |
Sectorielle
Health Technology | 9 |
Commercial Services | 3 |
Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 5 |
---|---|
LIDDS AB | Health Technology |
STAYBLE THERAPEUTICS AB | Health Technology |
ASTRAZENECA PLC | Health Technology |
ABLIVA AB | Health Technology |
ISOFOL MEDICAL AB | Health Technology |
Entreprise privées | 12 |
---|---|
Aqilion AB
Aqilion AB Investment ManagersFinance Aqilion AB is a venture capital firm. The firm was founded in 2002 by Jan Ekberg and Mats G. Ringesten. It's headquartered in Helsingborg, Sweden. | Finance |
Glactone Pharma Development AB | |
Innoex AB | |
Diaprost AB
Diaprost AB Miscellaneous Commercial ServicesCommercial Services Diaprost AB is a private pharmaceutical research and development company based in Lund, Sweden. Diaprost collaborates with leading international experts in the fields of molecular medicine, biotechnology, immunology, radiology, radiation physics, laboratory medicine, and oncology. The Swedish company has an agreement with a top 10 pharma company for its first antibody H11B6 targeting the HK2 antigen, which is in early clinical development. The remaining Diaprost pipeline consists of 5A10, which targets free-PSA antigen for both diagnostic and therapeutic applications. The company was founded in 2005 with the aim of leveraging the transformative success of the PSA assay for detection of prostate cancer as a personalized theranostic platform. Johan Drott has been the CEO of the company since 2015. | Commercial Services |
Stayble AB | |
Oncorena AB
Oncorena AB Pharmaceuticals: MajorHealth Technology Oncorena AB develops a novel pharmacological treatment for metastatic renal clear cell cancer. It conducts clinical trial for potential new therapies in humans. The company was founded in 2011 and is headquartered in Helsingborg, Sweden. | Health Technology |
Glactone Pharma AB
Glactone Pharma AB Pharmaceuticals: MajorHealth Technology Glactone Pharma AB engages in the development of pipeline of novel signal transducer and activator of transcription 3 inhibitors. Its pipeline is used for immuno-oncology and for the treatment of drug resistant cancers, including castration resistant prostate cancer. The company was founded by Anders Sigvard Bjartell, Rebecka Hellsten, Martin Johansson, Eduardo Munoz, and Olov Arvid Sterner in 2012 and is headquartered in Helsingborg, Sweden. | Health Technology |
Oncorena Holding AB
Oncorena Holding AB Pharmaceuticals: MajorHealth Technology Oncorena Holding AB develops novel pharmacological treatment for metastatic renal clear cell cancer. It conducts clinical trial for potential new therapies. The company was founded by Björn Oskar Larsson in 2011 and is headquartered in Helsingborg, Sweden. | Health Technology |
Lidds Pharma AB | |
Innoext AB
Innoext AB Miscellaneous Commercial ServicesCommercial Services Innoext AB provides management consulting services. The private company is based in Västra Frölunda, Sweden. Jan Birger Fredrik Toernell has been the CEO of the Swedish company since 2011. | Commercial Services |
Hammars Bryggeri AB
Hammars Bryggeri AB Beverages: AlcoholicConsumer Non-Durables Hammars Bryggeri AB engages in brewery operations. It produces a wide range of soft drinks, water, and other cider beverages. The company was founded in 1904 and is headquartered in Hammar, Sweden. | Consumer Non-Durables |
Puls AB
Puls AB Environmental ServicesIndustrial Services Puls AB is a private company based in southern Sweden that specializes in sewage, industrial, and environmental services. The Swedish company's on-call services include emergency stops in the drain, sewage cleaning, and wastewater flushing. The company also uses water blasting as an environmentally friendly method to clean tanks, cisterns, sheet metal, and boat hulls. Puls is the largest player in VA maintenance in southern Sweden and has a team of talented employees who specialize in water and wastewater in tenant-owner associations. The company offers preventive maintenance work and emergency measures to help associations with their maintenance needs. | Industrial Services |